Tromboembolismo pulmonar em uma paciente com AIDS com insuficiência venosa profunda, tuberculose pulmonar e câncer de mama: relato de um caso e revisão da fisiopatologia by Cortez-Escalante, Juan José et al.
Rev. Inst. Med. trop. S. Paulo
48(2):105-108, March-April, 2006
Research funded by CNPq.
(1) Núcleo de Medicina Tropical, Universidade de Brasília, Brasília, D.F. Caixa Postal 04517. Campus Universitário Darcy Ribeiro, Asa Norte, 70904-970 Brasília, DF, Brasil.
(2) Yale University School of Medicine. Section of Medical Oncology. 333 Cedar Street; FMP 116, New Haven, CT 06520, USA.
Correspondence to: Juan José Cortez-Escalante. Núcleo de Medicina Tropical, Universidade de Brasília, Caixa Postal 04517. Campus Universitário Darcy Ribeiro, Asa Norte, 70904-970
Brasília, DF, Brasil. Phone: +55 61 96562675; +55 61 2735008, Fax: 00 55 61 2732811. E-mail: jcorteze@unb.br
PULMONARY THROMBOEMBOLISM IN AIDS PATIENT WITH CHRONIC VENOUS
INSUFFICIENCY, PULMONARY TUBERCULOSIS AND BREAST CANCER:
A CASE REPORT AND PATHOPHYSIOLOGY REVIEW
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SUMMARY
Recent literature reports thrombotic episodes occurring in patients with HIV infection associated with other abnormalities
including neoplasms and infections predisposing to a hypercoagulable state. We report a 47-year-old woman who developed
pulmonary thromboembolism in association with HIV infection, pulmonary tuberculosis and breast cancer. She was treated with
rifampin, isoniazid, pyrazinamide; heparin, phenprocoumon, zidovudine, lamivudine and efavirenz. Acid fast bacilli were visualized
in a sputum smear and three months after, Mycobacterium tuberculosis was isolated from lymph node biopsy during a episode of
immune reconstitution. The isolated mycobacteria showed sensitivity to all first-line drugs. HIV infection, breast cancer and
pulmonary tuberculosis have several mechanisms that induce hypercoagulable state and can lead to thromboembolic complications.
Pulmonary thromboembolism in this patient was a diagnostic challenge because of all the other severe diseases that she experienced
at the same time.
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INTRODUCTION
The development of pulmonary thromboembolism (PTE) in patients
with the human immunodeficiency virus (HIV) infection is
uncommon13. Various hematological abnormalities have been associated
with HIV, including a hypercoagulable state predisposing to the
thromboembolic complications. It becomes worse with cancer,
opportunistic infections or autoimmune diseases and also with the use
of a wide chemotherapy25. PTE is a common, serious and potentially
fatal complication of the deep venous thrombosis (DVT). Both of them
are distinct but related aspects of the same dynamic disease process
known as venous thromboembolism (VTE). An estimated 201,000 new
cases occur in the United States every year, being 107,000 with DVT
(without PTE) and 94,000 with PTE (with or without DVT)30. In the
same population, PTE is estimated to cause 50,000 deaths annually16.
The most stressful situation is that the majority of deaths due to PTE
occur in patients who are not treated because the lack of opportune
diagnosis4. The frequency and magnitude of VTE in people living with
HIV/AIDS changes according to the study method. The reported
incidence has ranged from 0.25% to 0.96% in clinical studies, but up
to 17% at necropsy3. The risk of DVT in people living with HIV/AIDS
is approximately 10 times greater than in the general population24. In
Brazil, researchers reported data based on necropsies, GOLIN et al.
(2002), found 4.7% prevalence of PTE in 16,466 necropsies during 24
years in a tertiary level hospital, and YOO et al. (2003) 10.6% in 4813
necropsies in a period of 20 years in a similar scenario12,36.
It is known the relationship among the hypercoagulable state and
cancers. The most common tumor sites are colon, lung and prostate in
men, and breast, lung and ovary in women18. In the breast cancer patient,
the prevalence of DVT/PTE is 22 per 10,00019 and the incidence of
VTE vary from as low as 0.1% in stage I disease in untreated patients
to as high as 18% in stage III/IV disease in patients treated with
chemotherapy and hormones22. AIDS-related malignancies such as
Kaposi’s sarcoma, non-Hodgkin’s lymphoma, Hodgkin’s lymphoma
have been associated with DVT5,15. Frequency of VTE in patients with
tuberculosis is variable. DVT is clinically obvious in 3.4% of the
patients with pulmonary tuberculosis35. However, the real incidence
may be closer to 10%, because, ANDERSON et al. (1991), reported
that one-third of all such cases are thought to be apparent1. ROBSON
et al. (1996), found that 7.38% of their patients with pulmonary
tuberculosis presented PTE23. We report a patient with AIDS, pulmonary
tuberculosis, breast cancer and chronic venous insufficiency at the
University Hospital of the University of Brasilia.
CASE REPORT
A 47-year-old woman with past medical history of chronic venous
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insufficiency in the lower extremities for 18 years initially presented
with weakness, fever, night sweats, and weight loss of 12 kg over six
months. Review of systems included pain in the epigastrium, mild
dyspnea on exertion, and productive cough at the last four weeks. Patient
denied history of hormonal contraception use or hormone replacement
therapy. Physical examination demonstrated pale mucosa, tachypnea
(26 breaths/min), crackles on bilateral lungs auscultation, a hard, mobile
nodule of 4 cm of diameter in the upper outer quadrant of the left
breast without inflammatory signs. Scars of old ulcers were observed
in both legs. Chest radiographies and computed tomography-CT (Fig.
1) showed interstitial infiltrates in the lower two-thirds of both lungs.
A mammography and a breast biopsy showed two nodules, one of them
compatible with malignancy. Histopathology of the cervix showed mild
dysplasia and alterations compatible with human papillomavirus (HPV)
infection. Initial laboratorial evaluation showed positive HIV serology,
sputum positive for acid-fast bacillus, hemoglobin of 9.6 g/dL,
leukocytes of 7,400 cells/µL, platelets of 204,000 cells/µL, aspartate
aminotransferase (AST) of 97 UI/L, alanine aminotransferase (ALT)
of 64 UI/L, lactate dehydrogenase (LDH) of 508 UI/L, alkaline
phosphatase of 363 UI/L and total protein of 8.2 g/dL (albumin of 3.2
g/dL and globulin of 5 g/dL). The CD4+ T cell count was of 38 cell/
µL, CD8+ of 188 cell/µL (CD4/CD8 = 0.20) and the viral load was of
340,007 copies (log 5.531). The tuberculin skin test (PPD) was negative.
The repeat chest x-ray continued showing the same patterns detected
in the first radiography, one month before. During hospitalization anti-
tuberculosis therapy (ATT) was introduced with rifampin, isoniazid
and pyrazinamide. Following ATT, on fifth day, she developed
progressive dyspnea, tachypnea (34 breaths/min) and tachycardia (100
beats/min). On tenth day, she complained of acute chest pain in the
right anterior hemithorax with irradiation to the back on the same side,
which worsened during the inspiration. Differential diagnosis included
a concomitant infection like Pneumocystis carinii pneumonia or PTE.
Trimethoprim/sulfamethoxazole and heparin in prophylactic dose were
initiated. The CT pulmonary angiography revealed PTE in both main
pulmonary arteries, with extension to the lobar and segmental arteries
of the right lower lobe and to the lobar arteries of the left lower lobe
(Fig. 2). Therefore, anticoagulant therapy with heparin and oral
phenprocoumon was administered. The levels of activated partial
thromboplastin time (PPT) were between 1.12 to 1.54 times normal
and the levels of prothrombin time (PT) were frequently with an
international normalized ratio (INR) < 2. Few days after beginning
this therapy, the patient felt a significant improvement of the dyspnea.
After three months of ATT and highly active antiretroviral therapy
(HAART), she evolved with the immune reconstitution syndrome, with
cervical lymph-nodes of approximately 3.5 to 5 cm of diameter with
identification of the Mycobacterium tuberculosis in the acid-fast stain
and in the culture of lymph-node biopsy. The isolated mycobacteria
was sensitive to all ATT drugs, therefore, the medical indication was
to continue without modifications of the established therapy. She had
a mastectomy with axillary lymph-nodes removed. The diagnostic was
invasive ductal carcinoma, with a size of 3 x 2.7 x 2.5 cm, a surrounding
border of cancer-free tissue, and the nearby lymph nodes. An Estrogen
Receptor/Progesterone Receptor immunohistochemical investigation
was negative. Nowadays, 23 months after the acute PTE episode, she
stopped the anticoagulant therapy, continuing with low-dose aspirin
and she remains cured of tuberculosis. Her therapeutic response to
HAART was excellent maintaining undetectable levels of viral HIV
load and CD4+ cell counts above 200/µL.
REVIEW
Many risk factors are involved in the development of PTE, these
are the same for thrombus formation within the venous circulation,
Fig. 1 - Chest CT: Infiltrative lesions in lungs and cavitary lesion in the upper segment of the
lower left lobe, one month before hospitalization.
Fig. 2 - CT pulmonary angiography (a, b,): Thromboembolus (arrows) that obstruct the
pulmonary arteries and their branches.
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which can be grouped into three basic mechanisms as follows: venous
stasis, injury to the vessel wall and hypercoagulability states, described
by Virchow more than 100 years ago4. In patients with HIV infection
several abnormalities were detected that predispose to the
hypercoagulability state, including endothelial cell injury10, low-grade
disseminated intravascular coagulopathy9, interference with the
anticoagulation factors6,9,26,32 and the use of the drugs as protease
inhibitors31. The abnormalities of anticoagulant factors are characterized
by the presence of antiphospholipid antibodies (lupus anticoagulant,
anticardiolipin, antiprothrombin and antibeta-2 glycoprotein I),
deficiencies of the protein C9, protein S17, heparin cofactor II32 and
antithrombin III26; as well as enhanced levels of von Willebrand factor
and D-dimers9. This abnormalities are related to the severity of the
underlying immunosuppression (Low CD4+ T cell count), opportunistic
infections and malignancy induced by the HIV infection6. FEFFER et
al. (1995), reported that HIV patients with CD4+ counts below 200
cell/µL presented those alterations more frequently that those with
CD4+ counts above 400 cell/µL9. At least, some of those alterations
could be present in our patient and contributed to the development of
PTE. These abnormalities of anticoagulation factors could be reverted
with the specific therapy of the opportunistic infections6 and
antiretroviral therapy25. The association of cancer and thrombosis is
well described and certain neoplasms, including breast cancer, are
strongly associated with an increased frequency of thromboembolic
events. In the primary breast cancer, the neoplastic cells produce an
important quantity of tissue factor, the major extrinsic pathway
procoagulant, independently of the clinical stage of the breast cancer29,34.
In addition, the chemotherapeutic and hormonal agents used to treat
breast cancer are associated with damage to vascular endothelium,
lowered levels of endogenous anticoagulants (protein C, protein S and
antithrombin III) and an increased incidence of thrombosis, in both
the adjuvant and metastatic setting21,27. Severe pulmonary tuberculosis
is sometimes complicated by hypercoagulability states. These patients
have lower levels of anticoagulation factors (protein C, protein S,
antithrombin III), with elevation in plasma fibrinogen, factor VIII,
fibrinolytic protein PAI-1 and D-dimers. All these alterations improve
during the first 12 weeks of anti-tuberculosis therapy23,33. Anticardiolipin
antibodies are found in these patients, although relationship was not
demonstrated with the appearance of thromboembolic complications28.
Some hypercoagulability abnormalities in tuberculosis patients can
be explained. The Mycobacterium tuberculosis is able to activate
macrophages directly and induces them to produce cytokines11. Some
cytokines induce thrombosis, especially TNF-alpha, IL-1 and IL-6.
TNF and IL-1 block the protein C anticoagulant pathway and can elicit
tissue factor production on endothelium and monocytes. Thus, cytokines
induce tissue factor formation intravascularly. This contrasts with the
normal situation in which tissue factor is located exclusively in the
extravascular space, largely on fibroblasts, where it is expressed
constitutively7,8. The IL-6 can stimulate new platelets formation which
have increased sensitivity to thrombin activation and increased
procoagulant activity2. The presence of pulmonary tuberculosis with
cavitation in HIV patients with CD4+ counts below 200 cells/µL is an
uncommon finding. Mycobacterium tuberculosis, in immunocompetent
subjects, induces an early and late immune response that ultimately
destroys most tubercle bacilli and usually prevents development of
clinical disease. Early response is characterized by the presence of
macrophages with other immune cells and the late response is dependent
on the acquisition of CD4+ T cell-mediated immunity and characterized
by granuloma formation14. In immunodeficient AIDS patients it does
not happen, the immune response reacts poorly and form few cavitary
lesions in the pulmonary parenchyma20.
Because of the multitude of associated medical conditions and
pharmacological agents usually used to treat AIDS patients,
anticoagulation should only be started after a definitive diagnosis has
been made. Duplex ultrasound and venography remain the diagnostic
studies of choice to identify those patients who need anticoagulant
therapy and should be used aggressively in securing the diagnosis.
Although the relationship between the degree of immunosuppression
and incidence of thrombosis is not know but we found similar findings
as earlier published in our retrospective study of 131 patients26.
Thromboembolism is particularly worrisome, and its sequelae can lead
to sudden death (pulmonary embolus) in young patients. High degree
of suspicion should be made in patients with HIV infection who present
with signs and symptoms suggestive of VTE or PTE in spite of their
younger age. Therefore, clinicians caring for these patients should be
aware of the abnormalities which broaden the differential diagnosis of
patients infected with HIV. Further studies aimed to elucidate the
etiology of these proteins and related antibodies are needed.
Finally, the human immunodeficiency virus infection, breast cancer
and pulmonary tuberculosis have several mechanisms that lead
hypercoagulable state and can start venous thromboembolic
complications like pulmonary thromboembolism. Pulmonary
tuberculosis can disguise the apparition of PTE, as well as opportunistic
infections in AIDS patients. Diagnostic and treatment of PTE in AIDS
patients are similar with non-AIDS patients. HAART and anti-
tuberculosis therapy could revert the hematological abnormalities that
activate venous thromboembolism. Clinicians should be aware of
unprovoked thrombosis as a possible complication of AIDS and in the
differential of other pathologies such as PTE may mimic opportunistic
lung infections. In cases of unexplained thromboembolic events in
young patients, HIV testing should be considered, at least in high risk
groups.
RESUMO
Tromboembolismo pulmonar em uma paciente com AIDS com
insuficiência venosa profunda, tuberculose pulmonar e câncer de
mama: relato de um caso e revisão da fisiopatologia
Publicações recentes relatam episódios trombóticos em pacientes
infectados pelo HIV associados a outras condições que incluem
neoplasias e infecções que predispõem para um estado de
hipercoagulabilidade. Relata-se o caso de uma paciente de 47 anos
portadora do HIV que desenvolveu tromboembolismo pulmonar,
tuberculose pulmonar e câncer de mama. Foi tratada com rifampicina,
isoniazida, pirazinamida, heparina, femprocumona, zidovudina,
lamivudina e efavirenz. Bacilos ácido-álcool-resistentes foram
observados no exame de escarro e três meses depois foi isolado o
Mycobacterium tuberculosis da biópsia de linfonodo durante um
episódio de reconstituição imune. A micobactéria isolada demonstrou
sensibilidade a todas as drogas anti-tuberculosas de primeira linha. A
infecção pelo HIV, o câncer de mama e a tuberculose pulmonar possuem
vários mecanismos que induzem um estado de hipercoagulabilidade e
que podem produzir complicações tromboembólicas incluindo o TEP
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nos pacientes com AIDS. O TEP nesta paciente foi um desafio diag-
nóstico, considerando todas as outras doenças graves que apresentou
simultaneamente.
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